Characteristics and significance of T lymphocyte subsets in peripheral blood of osteosarcoma mice

Abstract

Background Osteosarcoma (OS) is the most common malignant bone tumor, which often has lung metastasis. The survival rate after tumor metastasis is very low. Treatments including the antitumor immunocompetence of innate immune cells are found favorable for OS tumor. However, as a major means of early tumor detection, there are still few studies on T cells in peripheral blood of OS patients. Methods OS cells were implanted into the femoral bone marrow cavity of C3H/HeN mice to construct OS model. The proportion of T lymphocyte subsets in peripheral blood of mice was detected by flow cytometry on the 14 th and 21 st days after modeling. Results Compared with sham operation group, on the 14 th day after operation, the proportion of γδT cells and CD4 + regulatory T cells (Tregs) showed significantly higher level while other subsets didn’t have obvious difference. On the 21 st day after operation, the proportion of CD3 + T cells, γδ T cells, CD4 + Tregs and Tregs/Th17 ratio were obviously higher than that of sham operation group. Meanwhile, while CD4 + T cells and CD8 + T cells were lower, suggesting the happen of peripheral immunosuppression. Comparing the T lymphocytes subsets on the 14 th and 21 st day after modeling in the tumor group, it was found that CD3 + T cells and CD4 + Tregs on the 21 st day after modeling were significantly higher than those on the 14 th day while CD4 + T cells, CD8 + T cells decreased significantly, indicating the changes of T lymphocytes in peripheral blood of OS mice are related to tumor development. Conclusions The formation and development of femoral OS is accompanied by the disorder of peripheral blood T lymphocyte subsets and peripheral immunosuppression.

A novel molecular signature for predicting prognosis and immunotherapy response in osteosarcoma based on tumor-infiltrating cell marker genes

“…Previous studies confirmed that Treg cells are involved in the tumor development process by suppressing antitumor immunity and its high expression level represents a poor prognosis ( 45 ). γδ T cells, a congenital cytotoxic T cells, were highly infiltrated in the low-risk group, which may be related to the fact that osteosarcoma is an immunocompromised tumor ( 46 ). Moreover, LAIR1, HAVCR2, CD27, CTLA4, CD48, CD44, LAG3 and LGALS9 were highly expressed in the low-risk group, indicating that the low-risk group was more likely to benefit from more types of immunotherapy.…”

A therapy that modulates T lymphocyte subsets in patients infected with Epstein-Barr virus: Ganciclovir combined with interferon atomization inhalation

“…It has been used as an important means of clinical research. [ 20 , 21 ] Decreased CD4+/CD8+ ratio is an important indication of immunodeficiency disease. In patients with acquired immunodeficiency syndrome, there is a significant reduction in the number of CD4+ cells, so the CD4+/CD8+ ratio is often inverted.…”

Guardians of Immunity: Advances in Primary Immunodeficiency Disorders and Management

“…One aspect of T-cell dysfunction in these disorders involves an imbalance in the expression of certain immune-related genes. For example, studies have shown that the expression of FOXP3, a gene involved in the function of regulatory T-cells, is reduced in patients with T-cell disorders [ 31 ]. Thymus-derived regulatory T-cells (Tregs) play a crucial role in immune regulation by suppressing the activation of other T-cell subsets, such as Th17 and Th1 cells [ 31 ].…”

“…For example, studies have shown that the expression of FOXP3, a gene involved in the function of regulatory T-cells, is reduced in patients with T-cell disorders [ 31 ]. Thymus-derived regulatory T-cells (Tregs) play a crucial role in immune regulation by suppressing the activation of other T-cell subsets, such as Th17 and Th1 cells [ 31 ]. This impairment of Treg-mediated immunosuppression, coupled with the increased expression of genes associated with Th17 and Th1 cells, suggests a dysregulation of the immune response in individuals with T-cell disorders [ 31 ].…”